Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 15501 - 15525 of 15795 in total
Investigational
Investigational
Investigational
Investigational
Emerfetamab is a bispecific T cell engager antibody construct with a half-life extension Fc moiety capable of binding to the neonatal Fc receptor.
Investigational
VBI-1901 is a bivalent cytomeglaovirus gB/pp65 enveloped virus-like particles
Investigational
Heat stable ricin vaccine is an alum-adjuvanted, heat stable recombinant subunit vaccine.
Investigational
Investigational
Recombinant human heparan-N-sulfatase (rhHNS) is under investigation for the treatment mucopolysaccharidosis type IIIA.
Investigational
LTI-03 is a caveolin-1 Scaffolding Domain 7-Mer
Investigational
DiaVacs is a CD40/CD80/CD86 modified autologous dendritic cell therapy
Investigational
Lusacomfar Alfa is a recombinant complement factor H
Investigational
RHCC10 is a recombinant human Clara cell protein.
Investigational
MUL001 is live attenuated strain of Salmonella typhimurium being investigated for the treatment of schwannomas.
Investigational
LB-P8 is an investigational live biotherapeutic product consisting of a single bacterial strain (Leuconostoc citreum).
Investigational
SNP-ACTH (1-39) is a synthetic porcine Corticotropin (ACTH)
Investigational
TTX-siPDL1 is an siRNA-based modulator of programmed death-ligand 1.
Investigational
mRNA-3745 is a lipid nanoparticle (LNP) encapsulated with nucleoside-modified, codon-optimized mRNAs encoding human glucose 6-phosphatase (G6Pase).
Investigational
AMT-101 is a recombinant human interleukin-10 fusion protein.
Investigational
MB-107 consists of mobilized peripheral blood-derived autologous CD34+ hematopoietic stem cells that are genetically modified to express the IL2RG gene.
Investigational
PBFT02 is a non-replicating recombinant adeno-associated virus serotype 1 vector delivering human GRN gene encoding the protein progranulin.
Investigational
Zelpultide alfa is a recombinant human surfactant protein D.
Investigational
AAV9/MFSD8 is a gene therapy developed by Neurogene Inc. It is an adeno-associated virus serotype 9 (AAV9) vector with an engineered transgene encoding the human CLN7/MFSD8 gene for expression of active human major facilitator superfamily domain containing 8. It was investigated for the treatment of neuronal ceroid lipofuscinosis type 7.
Investigational
Displaying drugs 15501 - 15525 of 15795 in total